3-(Allylthio)-indol | 54856-69-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(Allylthio)-indol
• 英文别名: 3-prop-2-enylsulfanyl-1H-indole
• CAS: 54856-69-8
• 化学式: C₁₁H₁₁NS
• 分子量: 189.281
• InChiKey: KHWYULSLQSEJAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  41.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  吲哚-3-基硫氰酸酯 、 3-溴丙烯 在 indium 作用下， 以 四氢呋喃 为溶剂， 反应 0.03h， 以87%的产率得到3-(Allylthio)-indol
  参考文献：
  名称：

  杂芳基、苄基和肉桂基硫氰酸酯的铟介导烯丙基化：3-(烯丙基硫烷基)-1H-吲哚的新途径

  摘要：

  杂芳基、苄基和肉桂基硫氰酸酯在铟或锌金属的存在下在 THF 中在室温下与烯丙基溴进行平滑的烯丙基化，以良好的收率和高选择性制备相应的烯丙基硫化物。

  DOI：

  10.1246/cl.2008.1082

文献信息

• Substituted indoles as alpha-1 agonists
  申请人：——

  公开号：US20030220319A1

  公开（公告）日：2003-11-27

  This invention relates to compounds which are alpha-1 receptor agonists, preferably alpha-1A/L receptor agonists, and which are represented by Formula I: 1 wherein X is —S(O) n — or —C(O)—, A is C 1-6 alkyl, aryl, heteroaryl, hydroxyalkyl, or —(CH 2 ) p —NR a R b , and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

  这项发明涉及α-1受体激动剂，优选为α-1A/L受体激动剂，其化学式如下：其中X为—S(O)n—或—C(O)—，A为C1-6烷基，芳基，杂环芳基，羟基烷基，或—(CH2)p—NRaRb，其他取代基如规范中所定义；或其各个异构体，消旋体或非消旋体混合物，或其药用盐或溶剂化合物。该发明还涉及含有这类化合物的药物组合物，以及它们作为治疗剂的使用方法和制备方法。
• Novel 2,5-Substituted Pyrimidines
  申请人：Grunenthal GmbH

  公开号：US20160024053A1

  公开（公告）日：2016-01-28

  The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.

  该发明涉及一种新型的取代紧缩嘧啶化合物，其一般式为(I)，其中化学基团、取代基和指数如描述中所定义，并且其用作药物，特别是用作治疗通过抑制PDE4酶可治疗的状况和疾病的药物。
• Indole and indoline derivatives
  申请人：MAY & BAKER LIMITED

  公开号：EP0042298A1

  公开（公告）日：1981-12-23

  Indole and indoline derivatives of the formula: wherein indicates a double bond or a single bond between carbon atoms, R1 represents an alkyl group containing 1 to 6 carbon atoms (which may be substituted by one or more than one of the same type of substituents selected from the hydroxy group, alkenyl groups containing 2 to 5 carbon atoms, and alkanoyloxy groups containing 2 to 7 carbon atoms) or a hydrogen atom, and one of the symbols R2 represents an alkyl group containing 6 to 24 carbon atoms and the other symbol R2 represents an alkyl group containing 1 to 24 carbon atoms, or a hydrogen atom, and R3 reptesents an alkyl group containing 1 to 6 carbon atoms or a hydrogen atom, are new compounds possessing useful pharmacological properties. They are of use in the treatment of diabetes mellitus, hyperlipoproteinaemic states, of atherosclerosis, and of associated disorders. Pharmaceutical compositions containing the compounds are described and so are numerous processes for oreparing the compounds.

  式中的吲哚和吲哚啉衍生物： 其中表示碳原子间的双键或单键，R1 表示含 1 至 6 个碳原子的烷基（可被一个或一个以上选自羟基、含 2 至 5 个碳原子的烯基和含 2 至 7 个碳原子的烷酰氧基的同类取代基取代）或氢原子、其中一个符号 R2 代表含 6 至 24 个碳原子的烷基，另一个符号 R2 代表含 1 至 24 个碳原子的烷基或氢原子，而 R3 则代表含 1 至 6 个碳原子的烷基或氢原子。它们可用于治疗糖尿病、高脂蛋白血症、动脉粥样硬化及相关疾病。本文介绍了含有这些化合物的药物组合物，还介绍了许多制备这些化合物的工艺。
• SUBSTITUTED 1-(4-AMINOPHENYL)INDOLES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：EP1303508A1

  公开（公告）日：2003-04-23
• SUBSTITUTED INDOLES AS ALPHA-1 AGONISTS
  申请人：F. Hoffman-la Roche AG

  公开号：EP1501826B1

  公开（公告）日：2006-09-27